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Abstract
Antibodies have been raised against synthetic peptides corresponding to several computer-predicted epitopes of three mtDNA-encoded 
subunits, ND4, ND5 and ND6, of the human respiratory chain NADH dehydrogenase (Complex I). Antibodies were characterized by a 
sensitive immunoblotting assay using proteins from human skeletal muscle mitochondria and by immunoprécipitation of radio-labeled 
HeLa cell mitochondrial translation products. Only antibodies against two of six selected peptides of the ND4 subunit, i.e., the C-terminal 
peptide and an internal peptide close to the C-terminus, reacted in both assays with the subunit. Antibodies raised against an internal 
peptide close to the N-terminus of the ND5 subunit and antibodies raised against an internal epitope of the ND6 subunit also reacted in 
both the immunoblotting and immunoprécipitation assays. The antibodies described above and other Complex I subunit- or holoenzyme- 
specific antibodies were used to investigate the subunit deficiencies of the respiratory NADH dehydrogenase in the skeletal muscle of 
patients affected by mitochondrial myopathies associated with Complex I defects. The reduction in enzyme activity correlated in an 
immunoblot assay with a decrease of four mtDNA-encoded subunits of the enzyme, as well as with a decrease of other subunits of 
Complex I encoded in the nDNA. The present work provides the first evidence of a decrease in NADH dehydrogenase subunits encoded 
in the mitochondrial genome in myopathy patients,
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1. Introduction It spans the mitochondrial inner membrane and oxidizes
NADH
Mitochondrial (encephalo)myopathies are a heteroge­
neous group of disorders affecting predominantly skeletal 
muscle and the central nervous system. A defect in the 
mitochondrial energy metabolism is thought to be the 
primary cause of disease. One of the respiratory chain
This large multimeric protein consists of at least 41 sub­
units (review [3]), including seven (called ND) subunits 
that are encoded in the mitochondrial genome [4,5].
Antibodies against Complex I subunits are very useful 
for studying the molecular basis of mitochondrial en-
enzymes that is frequently found deficient in various tis- cephalomyopathies. Polyclonal antibodies against purified 
sues of patients is NADH-ubiquinone oxidoreductase beef heart Complex I have been previously shown to react
(NADH dehydrogenase or Complex I, EC 1.6.99.3) [1,2].
Abbreviations: ECL, enhanced chemiluminescencc: FAB, fast atom 
bombardment; MELAS, mitochondrial myopathy, encephalopathy, lactic 
acidosis, and stroke-like episodes.
* Corresponding author. Fax: H-31 80 616428.
with only approximately 15 subunits ol the enzyme in 
human mitochondria. The use of these antibodies with 
skeletal mitochondrial proteins from myopathy patients 
showed a generalized reduction of all cross-reacting poly­
peptides, in some cases with a disproportionate and severe
The ND
not detected by these antibodies.
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Table 1
Amino acid sequences of selected peptides, as shown in Fig. 1
Peptide (Number) Amino acid sequence
ND4-I, ( 81- 94) SATA-Nlc-Gln-Arg-His-Leu-Ser-Ser-Glu-Pro-Leu-Ser-Arg-Lys-Lys-Leu
ND4-I-, (135-145) SATA-Nle-Arg-Trp-GIy-Asn-Gln-Pro-GIu-Arg-Leu-Asn-Ala
ND4-13 (277-285) SATA-Nle-Lcu-Arg-Gln-Thr-Asp-Leu-Lys-Ser-Leu
ND4-I4 (329-339) SATA-Nle-Leu-Ala-Asn-Ser-Asn-Tyr-Glu-Arg-Thr-His-Ser
ND4-I, (420-435) SATA-Nle-Thr-His-His-Ilc-Asn-Asn-Mct-Lys-Pro-Ser-Phe-Thr-Arg-Glu-Asn-Thr
ND4-C (451-459) SATA-Nle-Pro-Asp-Ile-Ile-Thr-Gly-Phe-Ser-Ser
ND5-I ( 2 1 -  35) SATA-Nle-Thr-Thr-Leu-Val-Asn-Pro-Asn-Lys-Lys-Asn-Ser-Tyr-Pro-His-Tyr
ND 6 -I3 (128-144) SATA-Nle-Glu-Gly-Glu-Gly-Ser-Gly-Phe-Ile-Arg-Glu-Asp-Pro-Ile-Gly-Ala-Gly-Ala
In brackets arc given the amino acid numbers corresponding to Anderson et al. [12]. The peptides were extended with L-norleucine (Nle) and 
S-acetylthioacetyl (SATA) at the amino-terminus for determination of the peptide-carricr ratio and coupling-procedures, respectively [14].
Antibodies against synthetic peptides corresponding to 
the C- or N-terminal regions of the human mtDNA-en- 
coded subunits have been previously used to identify the 
corresponding polypeptides by immunoprécipitation assays
[4,5,7,8] and, occasionally, by immunoblotting [9]. Anti­
bodies against peptides of predicted antigenic sequences 
can recognize epitopes on the whole protein [10,11]. Since 
the hydrophobic ND subunits are very difficult to purify
and have a low immunogenicity, we have raised antibodies 
against a few chemically synthesized peptides correspond­
ing to predicted epitopes. In this paper, we describe the 
preparation and characterization of antibodies against sev­
eral peptides of human mitochondrial NADH dehydro­
genase subunits ND4, ND5 and ND6, and the use of these 
antibodies, as well as of antibodies specific for other 
subunits of the enzyme, for the molecular analysis of
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Fig. 1 . The hydrophobicity profiles for the human ND4, ND5 and ND6  subunits. They are shown, as calculated with a sequence window of 9  residues, The
selected peptides (Table 1 ) are marked by boxes below the amino acid axis. Open or closed boxes indicate coupling of the peptides to either BSA with
MHS or OA with sulfo-MBS, respectively. I] and I2  below ND 6  indicate peptides (amino acid numbers 74—84 and 18—27, respectively) used by Chomyn 
et al. [5].
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Complex I defects in human mitochondrial myopathies. 
Multiple deficiencies of mtDNA- and nuclear-encoded 
subunits of this enzyme complex have been detected in 
myopathy patients, and shown to correlate with the sever­
ity of the enzyme defect.
2.4. Immunization of rabbits
2. Materials and methods
2.1. Selection and synthesis of peptides
The reported sequence of the human mitochondrial 
genome [12] was computer analyzed using the program 
PEPPLOT [13]. Criteria for selection of linear epitopes 
were hydrophilicity, surface probability, flexibility, high 
/3-turn and low «-helix or /3-sheet propensity [11]. The 
amino acid sequences of the selected peptides for ND4, 
ND5 and ND6 are shown in Table 1; their position in each 
subunit is shown in Fig. 1. Several candidate epitopes of 
ND4 were selected. The C-terminal peptide previously 
used by Mariottini et al. [8], even though it was not a 
predicted epitope by the criteria mentioned above, was 
synthesized for purpose of comparison. Only one internal 
epitope of ND5 and ND6 was chosen. For ND6, this was 
the only candidate epitope not used previously by Chomyn 
et al. [5]. The peptides were custom synthesized by Dr. 
G.I. Tesser (Laboratory of Organic Chemistry, University 
of Nijmegen, The Netherlands) by solid phase peptide 
chemistry. The peptides were extended with L-norleucine 
(Nie) and S-acetylthioacetyl (SATA) at the N-terminus for 
determination of the peptide-carrier ratio and coupling-pro- 
cedures, respectively [14].
2.2. FPLC, FAB mass spectra and amino acid analysis
Peptides were analyzed by reversed-phase chromatog-
Two rabbits were injected with each antigen at 2 -3  
week intervals. Each rabbit received a peptide-carrier pro­
tein conjugate mixed in a 1:1 (v /v ) ratio with the Freund’s 
adjuvant system (complete, FCA or incomplete, FIA, 
Difco). Conjugates of ND4~I3 and ND4-C were also tested 
with the Ribi adjuvant system (RAS, Sanbio). The admin­
istration of adjuvant preparations was as follows: FCA (1 
mg conjugate, total volume 2 ml) intradermally at 20 sites 
on the back of the animal; FIA (0.5 mg conjugate, total 
volume 1 ml) intramuscularly and subcutaneously;
(first dose 1 mg conjugate, thereafter 0.5 mg, each total 
volume 1 ml) at multiple places according to suggestions 
of the manufacturer. Blood samples were taken before the 
first injection (preimmune serum) and either 2 weeks after 
or immediately before the booster injections. The sera 
were prepared and stored at — 20°C. Before use, they were 
made free of antibodies against the carrier proteins by 
passing them twice over a column of carrier protein conju­
gated to CNBr-activated Sepharose (Pharmacia/LKB). y- 
Globulins were isolated by fractionating the sera over a 
Protein A Sepharose column (Pharmacia/LKB).
The rabbit antibodies against the 24 kDa subunit of 
bovine Complex I were raised using the purified protein 
over-expressed in Escherichia coli (Wilks, P.E., Medd, 
S.M. and Walker, I.E., unpublished data). The adenine 
nucleotide translocase (ANT) was isolated from bovine 
heart mitochondria by subsequent chromatography [15] 
and electrophoresis [16]. The ATPase (Complex V) was 
purified from human heart mitochondria by blue native 
electrophoresis [17]. Antibodies were raised in rabbits by 
inoculation of the purified proteins into the popliteal lymph 
nodes according to Sigel et al. [18]. The antibodies against 
the ATPase react mainly with the /3-subunit in an im- 
munoblot assay (results not shown). The antibodies against
raphy using a PepRPC HR 5 /5  column (Pharmacia/LKB) the bovine Complex I holo-enzyme and the ND1 subunit 
and a continuous gradient of acetonitrile (0-40%, v /v )  in
0.1% (v /v ) trifluoroacetic acid created by an FPLC system 
(Pharmacia/LKB). FAB mass spectra of collected peak 
fractions were analyzed by Dr. G. van de Werken (Na­
tional Institute of Health, Bilthoven, The Netherlands). The 
samples were hydrolyzed with 6 M HC1 for 1 h at 150°C 
or 18 h at 120°C in vacuum hydrolysis tubes (Pierce). The 
amino acid content of the hydrolysates was determined 
with an Alpha-Plus amino acid analyzer (Pharmacia/LKB).
of Neurospora crassa were kind gifts from Dr. U. Har­
nisch (Department of Biochemistry, University of Düssel­
dorf, Germany) and Dr. S. Werner (Department of Physio­
logical Chemistry, University of Munich, Germany), re­
spectively. The former showed a reaction with approxi­
mately 10 subunits of Complex I preparations from bovine 
and human heart tissue (results not shown). The latter were 
raised against a highly conserved peptide which has 12
14 amino 
sequence [19].
with the human
2.3. Coupling of peptides to carrier proteins
2.5. Enzyme-linked immunosorbent assay (ELISA)
Peptides were coupled to the carrier proteins bovine 
serum albumin (BSA), myoglobin (MYO) or ovalbumin 
(OA, all from Sigma) with 6-maleimidohexanoic acid N- 
hydroxysuccinimide ester (MHS, Pierce) according to 
Schielen et al. [14], except that 6-maleimidobenzoic acid 
JV-hydroxysulfosuccinimide ester (Sulfo-MBS, Pierce) was 
used as a linker in some cases.
Antibody titers were determined by ELISA assays es­
sentially as described by GeerKgs et al. [20], using the 
peptides coupled with a different linker to a different 
carrier protein as coating antigens, in order to exclude any 
cross reactions. The titer is defined as the reciprocal of the 
serum dilution giving an ELISA-signal above background
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(no serum addition), equivalent to twice the -sum of the 
mean background and its- standard deviation. The antibod­
ies raised against the carrier and the linking part were also 
assayed. The specificity of each reaction was investigated 
by testing the serum sample after a preincubation with the 
corresponding peptide.
2.6. Labeling and immunoprécipitation of mitochondrial 
translation products
HeLa cells were labeled for 2 h with [35S]methionine 
(20-50 ¿iCi/ml; 1000-1500 Ci/mmol) in the presence of 
emetine, an inhibitor of cytoplasmic protein synthesis, at 
100 yu.g/ml, and at a cell concentration of 2 • 106/m l [21], 
whereafter the mitochondrial fraction was isolated [7]. 
Immunoprécipitation was carried out using a SDS lysate of
Seven patients were selected for this study based upon 
extensive biochemical analysis which pointed towards a 
Complex I deficiency. A  brief overview of some clinical 
features and laboratory data is presented in Table 2. Con­
trol specimens were considered those in which a mitochon­
drial defect had been excluded by normal substrate oxida­
tion rates and individual enzyme measurements, as previ­
ously described [24].
P5 and P7 are patients diagnosed in our hospital with 
the MELAS syndrome; both carry an A to G transition at 
position 3243 in approximately 50% of their skeletal mus­
cle mtDNA (Van Oost, B.A., personal communication). 
All other patients and controls lack this as well as other 
known mtDNA mutations associated with mitochondrial 
myopathies or respiratory chain defects [25]. P5 and P6 are 
previously described patients [26,27].
this fraction as described previously [8], except that 80 jug 
of mitochondrial suspension (15 • 104 cpm) was used in 
each experiment. For each reaction either 8.5 ¡x\ of anti­
serum or 85 /mg of the y-globulin fraction was used. 
Inhibition by peptides was tested by adding to the serum 5 
¡x\ peptide solution in dimethylsulfoxide (DMSO) at 1 
m g/m l. Where stated, 5 /¿I DMSO was used as a control. 
The final immunoprecipitates were run on a 15-20% 
(w /v ) exponential gradient SDS polyacrylamide gel [22] 
and prepared for fluorography [23]. The previously de­
scribed antibodies against ND4-C(451-459), ND5-N(l-7), 
ND5-C(598-603) and ND6-Ij(74-84) were used for refer­
ence purposes [4,5].
2.8. Enzyme measurements
The activities of the rotenone-sensitive NADH- 
ubiquinone-1 oxidoreductase (Complex I), succinate-cyto- 
chrome-c oxidoreductase (Complex II-III), cytochrome-c 
oxidase (Complex IV) and citrate synthase were measured 
in 600 X g  supernatant or, where stated, in mitochondria 
of homogenized skeletal muscle as described previously 
[24]. The activities in 600 X g supernatants from fresh 
biopsy muscle were first normalized for citrate synthase 
activities. All activities are expressed as a percentage of 
the mean of controls. Ubiquinone-1 was a gift from Hoff- 
man-La Roche, Basel, Switzerland.
2.7. Patients and controls
Specimens of the quadriceps muscle were removed by 
biopsy from patients suspected to have a defect in oxida­
tive phosphorylation. From patients PI and P6 also au­
topsy material removed within 1 h after death was studied.
2.9. SDS-polyacrylamide gel electrophoresis and western 
blotting
Mitochondrial proteins, isolated by differential centrif­
ugation of homogenized skeletal muscle specimens, were
Table 2
Clinical, laboratory and morphological features of patients studied
Patient/sex
Diagnosis
1 /F
enccphalomyopathy
2 /F
myopathy
3 /M
encephalomyopathy
4 /M
encephalomyopathy
5 /M
MELAS
6 /F
encephalomyopathy
7 /F
MELAS
Age at onset 8 inf inf inf inf 2 2 4 inf
Age at biopsy “ 1 2  d 14 81 d 16 d 25 17 2 0
Progression ” +27 d +81 d +30 d slow +17 + 2 0
Hypotonia -h — + ****** -------
Strokes — — — — + f*tm*m +
Seizures + — • ( - — + — +
Retinopathy na — — — — * — na
Deafness na — na na + — +
Lactic acidosis + — + ■ i| ^ + + +
RRF — — — — + — +
Family history
*
— 4 - — 4 "
— + +
Complex I b 13 13 14 2 0 27 2 2 1 1 34
Complex II-III b 98 77 49 1 0 1 77 751! 57
Complex IV b 8 8 1 1 2 1 0 2 104 57 6211 97
" In years unless otherwise specified; inf, infantile; d, days; 11, autopsy; na, not available. 
Activities in 600 X g  supernatant are expressed as a percentage of the mean of controls.
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biotinylated swine anti-rabbit immunoglobulins, a 1:10000 
dilution of a streptavidin/biotinylated horse radish peroxi­
dase mixture (both Dako) in PBST with 1.5% (w /v ) BSA 
and 1% (v /v ) normal swine serum (Dako), each for 1 h. 
The y-globulins (1 m g/m l) were diluted 100 to 2000-times 
in PBST with 0.5% (w /v ) BSA, and occasionally, as 
specified below, preincubated for 1 h with 0.25 m g/m l 
peptide dissolved in DMSO; samples preincubated with 
the same amount of DMSO served as a control. Between 
the various steps the strips were washed three times with
et Biophysica Acta 1234 (1995) 63-73  67
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PBST. The ECL kit (Amersham) was used for detection of 
bound antibodies.
Rabbit antibodies raised against ANT or the ATPase 
complex were used as an internal standard for mitochon­
drial protein recovery at a dilution of 1:2000. Quantitation 
of the blots was carried out by scanning the films with a 
LKB laser densitometer.
Tabic 3
Antibody titers against peptides, carrier proteins or linkers
3. Results
3.1. Analysis and coupling of peptides
Reversed phase chromatography showed that the pep­
tides were pure to the extend of 70% or more (results not 
shown). Mass spectrometric analysis of the major peaks 
confirmed the expected mass of the peptides, indicating 
complete removal of the protecting groups. The crude 
peptide preparations were coupled to carrier proteins with­
out further purification, since only the full-length products 
were expected to contain the SATA group necessary for 
coupling [14]. Coupling ratios were determined by amino 
acid analysis of the conjugates comparing the amount of 
L-norleucine (specific for the peptides) with that of amino 
acids found only in the carrier proteins. Coupling ratios 
were 3-10 and 7-20  peptides per OA or BSA carrier 
molecule, respectively. The maximum available free amino 
groups in both carrier proteins are 10 and 27, respectively
[113.
Antibody Titer (X 1 0 3) against
peptide carrier linker
ND4-I, 197 90 8 . 1
ND4-I2 197 90 8 . 1
ND4-I,
vi*
142 (1.9) 91 (3.6) 0.3 ( < 0.03)
ND4-14 656 810 0.9 ■
ND4-I5 6 6 270 25
ND4-C 161 ( 1 .6 ) 280 (7.7) 0.9 ( <  0.03)
ND5-I 656 810 1 . 8  11
ND6-13 73 810 0.9 *
Sera were prepared from blood samples taken after three immunizations. 
The values are averages of data for two animals; between parentheses are 
the titers for RAS treated animals.
11 Indicates protocols using BSA/MHS as carrier/linker combination; in 
all other cases, OA/sulfo-MBS was used.
3.2. Antibody production
Antibody titers reached maximum values after three 
immunizations. All rabbits responded to the conjugates 
used for immunization. In the first experiments, the RAS- 
treated animals showed antibody titers that were lower, by 
a factor 10 to 40, than those of FCA/FIA-treated animals 
(Table 3). The linkers (MHS or sulfo-MBS) produced only 
low levels of antibodies in all animals, except for those 
immunized with ND4-I5. MHS has already been shown to 
be poorly immunogenic [30], All subsequent experiments 
were done with the sera from the FCA/FIA-treated ani­
mals.
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Fig. 3. Analysis of subunit-specific antibodies by Western blotting. Western blots of skeletal muscle mitochondrial proteins tested with antisera against 
ND4-I5, ND4-C, ND5-I and ND6 -I3. Mitochondrial proteins (2 fig) isolated from skeletal muscle of a control individual (Cl in Fig. 5) were separated on 
a 16.5% SDS-polyacrylamide gel according to Schagger and Von Jagow [28]. The ND4-specific antibodies were both diluted 1000-times, the ND5- and 
ND 6 -specific antibodies, 100-times. The ECL system was used for detection. The exposure time was 15 s for the ND4-IS, ND4-C and ND6 -I3  lanes, and 
30 s for ND5-I, A, and B. +  indicates a preincubation of the antiserum with the specific peptide preparation in DMSO (final concentration 0.25 mg/ml); 
-  indicates a preincubation with the same volume of DMSO. In lanes A and B, no primary antibodies \Mcre added; in lane B, also the incubation with the 
secondary (biotinylatcd) antibodies was omitted. On the left, the migration positions of water-soluble molecular weight marker proteins (Bio-Rad) are 
indicated.
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3.3. Immunoprécipitation capacity of subunit-specific anti­
bodies
The results of the immunoprécipitation studies are 
shown in Fig. 2. Lane M shows the pattern of HeLa cell 
mitochondrial translation products labeled with [35S]meth-
ionine in the presence of emetine. Note the migration of 
ND6 as a doublet in the exponential gradient system used 
here [22] (see Discussion). It appears from Fig. 2 that only 
antibodies against ND4-I5 and ND4-C were capable of 
immunoprecipitating the labeled ND4 subunit, in a reac­
tion inhibited by the specific peptide. This immunoprécip­
itation was as effective as that observed with the ND4-C 
antiserum described by Chomyn et al. [4] (results not 
shown). The other ND4 peptide-specific antibodies were
negative in
Also the antibodies against ND5-I and ND6-I3 precipi­
tated the ND5 and ND6 subunit, respectively, the reaction 
with each protein being inhibited by the corresponding 
peptide. The ND5 subunit could be visualized only after 
long exposure of the film. This resulted in some back­
ground of non-specific bands not inhibited by the specific 
peptide (Fig. 2). Antibodies against C- and N-terminal 
peptides of ND5 showed no reaction (results not shown).
Our ND6-I3 peptide antibodies precipitated ten times 
more ND6 than the ND6-I, antiserum, which has been 
used previously to identify ND6 as a NADH dehydro­
genase subunit [5]. The immunoprecipitated ND6 migrated 
in the gel as a doublet as in the original sample (lane M in 
Fig. 2). The higher molecular weight bands in the ND6-I3 
( -  pept) lane may be a result of aggregation during the 
assay [5]. Purified y-globulins gave an identical immuno­
précipitation pattern as total serum (results not shown).
3.4. Analysis 
blotting
It-specific antibodies by Western
Fig. 3 shows the results of Western blotting experi-
SDS-polyacrylamide gel elec-ments out
by using mitochondrial proteins from human
and y-globul in-fractions asskeletal
peptide-specific antibodies. With the ECL detection system 
2 fig of mitochondrial protein per lane was already suffi­
cient a signal. Total serum gave a very high 
signal, in part caused by the high levels of
carrier proteins (results not shown).
Therefore, purified y-globulin-fractions, from which the 
anti-carrier-antibodies had been removed, were used.
The antibodies against ND4-I5 and ND4-C reacted very 
strongly with a protein of apparent molecular mass of 39 
kDa (as estimated from its electrophoretic mobility, rela­
tive to that of water-soluble marker proteins), the reaction 
being inhibited by the specific peptide (Fig. 3, first four 
lanes). The molecular mass of this protein is in agreement
with that previously reported for bovine and human ND4, 
on the basis of its electrophoretic mobility in SDS-poly- holoenzyme-specific antibodies were used to analyze the
acrylamide gels [4,9,31]. The difference in size estimate 
relative to that predicted from the DNA sequence is due to 
the use, in the experiments cited above, of hydrophilic 
marker proteins, which bind less SDS than the hydropho­
bic mitochondrial translation products [8]. The antiserum 
against ND4-I5, which has 12 of 16 amino acids identical 
with the homologous bovine sequence, also reacted with a 
mitochondrial protein from bovine heart of approximately 
the same molecular mass (results not shown). The other 
ND4 peptide-specific antibodies were negative even in up 
to 100-fold lower dilutions (results not shown).
The antibodies against ND5-I and ND6-I3 also showed 
peptide-specific reactions. The ND5-I-specific antibodies 
produced two bands in a reaction that could be inhibited 
by the specific peptide. In particular, they gave a strong 
reaction with a protein of apparent molecular mass of 51 
kDa, and a minor reaction with a protein of a somewhat 
higher electrophoretic mobility (Fig. 3, fifth and sixth 
lane). The 51 kDa protein has the electrophoretic mobility, 
in an SDS-polyacrylamide gel, expected for the ND5 gene 
product, the difference from the mass expected for this 
product (66 kDa) being due to the bias in size estimates 
which was mentioned above. The minor reaction with the 
protein moving faster than the ‘51 kDa’ protein could be 
explained as resulting from a cross-reaction with another 
mitochondrial protein with a similar or identical ND5-I 
epitope(s); however, a computer search did not yield a 
known protein containing a sequence homologous for the 
amino acid sequence used. The ND6-I3-specific antibodies 
gave a specific reaction with a protein of apparent molecu­
lar mass of ~  8 kDa, as estimated relative to the marker 
proteins (Fig. 3). Here, too, the difference in molecular 
mass from that predicted from the DNA sequence (18.6 
kDa) is due to the bias in size estimates introduced by the 
use of hydrophilic proteins for the standard curve [8]. Both 
the ND5-I- and ND6-I3-specific antibodies gave a weak 
reaction in the immunoblot as compared to the ND4 
antibodies. Therefore, 10-times less diluted antibodies and 
also longer exposure times with the ECL system, in the 
case of ND5, had to be used. This caused the rather high 
background in lanes ND5-I and ND6-I3 in Fig. 3. The 
background in the upper portion of the lanes is most likely 
caused by biotin-containing proteins reacting with the 
streptavidin/horseradish peroxidase biotin complex, as 
shown in lanes A and B, where the primary and, in lane B, 
also the secondary antibodies, were omitted during the 
incubations. The molecular weights of the slower-migrat- 
ing proteins (arrows) are in agreement with those of biotin 
containing carboxylases, as reported by Robinson et al.
[32].
3.5. Immunoblotting of skeletal mitochondrial proteins from 
myopathy patients with subunit-or holoenzyme-specific an­
tibodies
The antibodies produced here and other subunit- or
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quantitative behaviour of the corresponding subunits in the 
respiratory NADH dehydrogenase of skeletal muscle from 
mitochondrial myopathy patients exhibiting an enzymatical 
Complex I deficiency.
Fig. 4 shows that antibodies against the bovine Com­
plex I holoenzyme (panel a) and against the ND1 peptide 
of Neurospora crassa (panel b) both gave weaker reac­
tions with mitochondrial proteins from patients P1-P5, as 
compared to the reactions observed with material from 
control individuals; patients P6 and P7 were not investi­
gated with these antibodies. Antibodies against the bovine 
Complex I holoenzyme gave a specific reaction with ap­
proximately ten proteins when tested against a Complex I 
preparation from bovine or human heart tissue (results not 
shown). Their position is indicated by arrowheads in Fig.
4, part a. These are probably all encoded in nDNA. The 
background in the upper portion of the lanes is, again, 
most likely caused by biotin-containing proteins reacting 
with the streptavidin/horseradish peroxidase biotin com­
plex, as shown in Fig. 3. The bands marked with asterisks 
in the lower portion of the patient lanes PI, P3 and P4,
which have a stronger intensity or a different mobility, as 
compared to the bands from control individuals migrating 
at the same positions, are probably degradation products. 
Note that the strong reaction with a protein of apparent 
molecular mass of 24 kDa in the patient lanes of Fig. 4 is 
not the result of a reaction with antibodies against the 24 
kDa subunit of Complex I (shown in Fig. 5).
The reaction with antibodies against the human ATPase 
/3 subunit also exhibited a normal intensity in the samples 
from patients P1-P5, as compared to the controls (Fig. 5, 
panel c), indicating the absence of significant differences 
in the purity of the mitochondria.
Fig. 5 shows that antibodies against the ND4-I5, ND5-I 
and ND6-I, peptides, as well as antibodies against the 
purified bovine 24 kDa FeS protein of Complex I, which is 
encoded in the nuclear genome, gave weaker reactions 
when tested with material from all seven patients studied, 
as compared to the reactions with samples from control 
individuals. This was not caused by differences in the 
purity of the mitochondria, because, except for patient P4, 
no large differences were seen among the various samples
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Fig. 4. Western blots using antisera against whole Complex I, its ND1  subunit and the ATPase /3 subunit. Control and patient mitochondrial proteins (2 
fig each) were separated on two identical 10% SDS-polyacrylamide gels [28]. Panel a shows a portion of one blot incubated with antibodies against the 
bovine Complex I holoenzyme. The positions of the 24 kDa, 75 kDa and other subunits, which show a reaction between the antibodies and blots of purified 
Complex I preparations, are indicated on the left. On the right, the migration positions of water-soluble molecular weight marker proteins (Pharmacia/LKB) 
are indicated. The other blot was cut into horizontal strips. Panel b shows the reaction with antibodies against the ND1 peptide of Neurospora crassa. 
Panel c shows the reaction with antibodies against the /3-subunit of human ATPase. The asterisks in lanes PI, P3 and P4 indicate the positions of possible 
degradation products (see Discussion). The ECL system was used for detection in all blots.
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Fig. 5. Western blots using antisera against the ND4, ND5, ND6  and 24 kDa subunits of Complex I or the ANT protein. Control and patient mitochondrial 
proteins (2 /xg each) were separated on a 16.5% SDS-polyacrylamide gel [28], After the transfer, the nitrocellulose paper was cut into four horizontal strips 
corresponding to the expected molecular weights of the subunits of interest and the parts were incubated with antibodies against ND4-IS and ND5-I, 
ND6 -I3, 24 kDa protein or ANT. The activity of Complex I in the isolated mitochondria is given below each lane. It is expressed as a percentage of the 
mean of controls (mean ±  S.D.: 168 ±  59 (n = 1 1 ) or 200 ±  85 nmol/min per mg protein (n — 15) for mitochondria isolated from frozen or fresh muscle 
homogenate, respectively). * Indicates the position of the band cross reacting with the ND5-I antibodies (see also Fig. 3).
in the reaction with antibodies against the bovine ANT 
protein (Fig. 4, bottom) or human ATPase /3 subunit (Fig. 
4, panel c). The strong reduction of ANT in mitochondria 
from patient P4 may have been caused by an additional 
deficiency of ANT protein in this patient. Support for this 
interpretation comes from the observation that the protein 
cross-reacting with the ND5-I antibodies, which is marked 
by an asterisk in Fig. 5, appeared to be present in mito­
chondria of patient 4 in the same amount as, e.g., in the 
samples of P5 and P6, which show a good reaction with 
the ANT-specific antibodies. The possibility of an ANT 
deficiency in patient P4 is presently under further investi­
gation.
There is a good correlation between the signal of im- 
munodetected Complex I subunits, as determined by den­
sitometry, and the activities of Complex I in b 
mitochondria from different individuals, as shown in the 
lower part of Fig. 5. The correlation coefficients for the 
ND4, ND5, ND6 and 24 kDa subunits, normalized for the 
ANT signal, were 0.82, 0.93, 0.86 and 0.92, respectively. 
Patients PI, P2, and P3, who exhibit a complete or near- 
complete absence of enzyme activity, appear to contain 
negligible amounts of the tested Complex I subunits in 
their skeletal muscle mitochondria. Patients P5, P6 and P7, 
who have moderately or substantially decreased Complex I
activities, show a proportional reduction in reactivity of 
their mitochondrial proteins with all four Complex I sub­
unit antibodies, whereas they exhibit amounts of ANT and 
ND5-I cross-reacting protein comparable, e.g., to those of
control C4.
4. Discussion
We have shown that it is possible to raise antibodies 
successfully against computer-predicted linear epitopes of 
mitochondrial membrane proteins. Furthermore, these anti­
bodies were shown to react with the corresponding pro­
teins not only in immunoprécipitation assays, but also in 
Western blots. Using the Ribi adjuvant system for immu­
nization, consistently much lower antibody 
observed, as compared to the immunizations carried out 
with the Freund’s adjuvant (Table 3). This phenomenon 
has previously been observed in rabbits using rat microso­
mal epoxide hydrolase as an antigen [33].
Only two of six epitopes of ND4
antibodies positive in both the immunoprecipitation 
the immunoblot assays. These were the C-terminal
(L) to it. Feamleyand an internal
Walker [34] predicted that all five internal 
situated between transmembrane segments. Whether
; are incorrect, or is do not
form linear epitopes in the presence of SDS is not clear at
Antibodies against internal peptides of ND5 and ND6 
reacted also in both the immunoprecipitation and the im­
munoblot assays. For ND5, these are the first antibodies 
reported with this capacity. The previously-tested ND5-N
and ND5-C peptide-specific antibodies [8] were not capa-
of ND5. In immunoblot
observed reaction with two bands 
could be inhibited by preincubation of the ND5-I antibod-
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ies with its corresponding peptide. The protein correspond- degmdation products. This degradation phe-
ing to the upper, strong band is most likely ND5, because nomenon has been previously observed by Robinson [35].
it has the expected molecular mass, as estimated relative to A generalized reduction of immunoreactive Complex I
hydrophilic marker proteins, and because it is reduced in subunits has previously been found in mitochondrial my-
amount in mitochondria from Complex I-deficient patients. opathy patients with a Complex I deficiency by immuno-
The lower, weak band may have been produced by a blotting experiments utilizing polyclonal antibodies against
reaction with an unknown protein containing a sequence bovine Complex I and antibodies specific for six nuclear-
homologous to the ND5-I peptide sequence. encoded iron-sullur proteins [1,6]. However, the mtDNA-
In the exponential gradient gel system used here, the encoded subunits were not identified in these experiments.
ND6 subunit migrated as a doublet band, possibly resulting Therefore, the present work provides the first evidence of a
from an unknown post-translational modification of a frac- decrease in the latter subunits in mitochondria of myopa-
tion of the protein molecules. The immunoprecipitated thy patients. It was found here that the remaining amount
ND6 also appeared as a doublet. In electrophoretic runs of of reacting subunits correlated with the residual Complex I
proteins from in isolated HeLa cell mitochondria and of 
fibroblast whole-cell extracts, ND6 has always been found 
to migrate as a doublet, making the possibility of prote­
olytic degradation as the cause of the doublet formation 
less likely (H. Bentlage, unpublished observations). Also 
in 20 cm long 16.5% acrylamide gels using the Tricine 
buffer system [28] ND6 appeared as a doublet band (re­
sults not shown). The strong immunoprécipitation reaction 
of the ND6-I3 antibodies, as compared to the ND6-I, 
antibodies, can be explained by a difference in either the 
titer or affinity of the two types of antibodies. The nature 
of the difference was not further investigated. In the 
Western blotting experiments, ND6 appeared as a single 
band, probably because of a different size (8 cm) of the gel 
system used.
In the immunoblots, it was essential to use y-globulin 
fractions depleted of antibodies to the carrier proteins in 
order to reduce the background. The remaining back­
ground could be partially explained by the presence of 
biotin-containing proteins in skeletal muscle mitochondria. 
A lower background appeared in the immunoprécipitation 
assays, since only 13 proteins were labeled that could give 
rise to non-specific signals.
The antibodies produced in the present work and other 
subunit- or holoenzyme-specific antibodies were used to 
investigate the presence and amount of mtDNA- and nu- 
clear-encoded subunits of the respiratory NADH dehydro-
genase in the skeletal muscle of by
myopathies associated with a Complex I deficiency. The 
results obtained indicated lower levels of the 
mtDNA-encoded subunits (ND4, ND5 and ND6) and one 
nuclear encoded subunit (24 kDa) in all seven patients 
studied. Also ND1 and several other nuclear encoded 
subunits were found to be less abundant in five patients 
studied, when ND1 peptide-specific and Complex I 
holoenzyme-specific antibodies, respectively, were used. 
The latter antibodies gave a reaction, in the samples from 
patients, with two bands that were either not present (20 
kDa) or less strongly represented (24 kDa) in the samples 
from control individuals. The band that migrated with an 
apparent molecular weight of 24 kDa in the samples from 
patients (Fig. 4) was shown not to react with 24 kDa 
subuniKspecific antibodies (Fig. 5). Both bands probably
activity in the skeletal muscle mitochondria
In the case of the two MELAS patients (P5 and P7), a
rate of mitochondrial protein synthesis [36,37] 
would account for the reduced amount of mitochondrial 
translation products and a resulting decreased assembly of
I. In the other patients, the underlying defect 
could again be a reduced protein synthetic capacity, or a 
disturbed assembly and subsequent degradation of Com­
plex I subunits. The latter process has been shown to occur 
in a HeLa cell mutant lacking the ND4 subunit [38]. 
Whether this pathogenetic mechanism operates in any of 
our patients remains to be determined. The antibodies 
described here will be useful for identifying defects in 
biosynthesis or stability of subunits encoded in mtDNA.
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